Vaccine Demand Boosts GlaxoSmithKline's Q2 Sales, Earnings; Maintains FY21 Guidance

  • GlaxoSmithKline Plc's GSK turnover was £8.1 billion in Q2, up 6% Y/Y (actual exchange rate AER), 15% (constant exchange rate CER).
  • Pharmaceuticals sales reached £4.2 billion, up 3% AER, 12% CER, driven by strong growth in New & Specialty products, favorable US RAR adjustments, and a prior year comparator impacted by destocking of COVID-19 related first quarter additional demand.
  • Vaccines sales grew 39% AER, 49% CER to £1.6 billion, primarily driven by pandemic adjuvant sales, higher demand for DTPa-containing vaccines in the US, and higher demand for Bexsero.
  • Vaccines turnover excluding pandemic vaccines grew 16% AER, 24% CER to £1.3 billion. 
  • Sales of its meningitis vaccine rose 46%, with shots for hepatitis and diphtheria up 28% as traditional hospital and doctor appointments rebounded from the COVID-19 disruption.
  • Adjusted operating margin of 26.7% was 3.7 percentage points higher at AER and 5.6 percentage points higher on a CER basis than in Q2 2020.
  • Adjusted EPS was 28.1p, up 46% AER, 71% CER.
  • The net cash inflow from operating activities was £1.3 billion. The free cash outflow was £316 million.
  • Outlook: GlaxoSmithKline reaffirmed 2021 adjusted EPS outlook to decline by mid-to-high single-digit percentage at CER.
  • As Shingrix sales are recovering more slowly in ex-US markets, the Company expects vaccines revenue for 2021 to be broadly flat.
  • Price Action: GSK shares are down 1.44% at $38.95 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!